Company Overview - Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on oncology and obesity, aiming to help patients overcome serious illnesses through innovative scientific approaches targeting well-understood biological pathways [2] - The company's pipeline includes three key products: CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for obesity treatment [2] Upcoming Events - Yuval Cohen, Ph.D., CEO of Corbus, will provide a corporate update and engage in one-on-one investor meetings at the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025, in New York [1] - The presentation by Corbus is set for June 4, 2025, at 4:55 p.m. ET [2]

Core Insights - Tactile Systems Technology, Inc. will participate in two investor conferences in June 2025, presenting at the William Blair 45th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference [1][2] Company Overview - Tactile Medical specializes in developing and marketing at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [3] - The company aims to improve the quality of life for patients by collaborating with clinicians to enhance clinical evidence, raise awareness, increase access to care, and reduce overall healthcare costs [3]

Core Points - I-Mab, a U.S.-based global biotech company, focuses on developing precision immuno-oncology agents for cancer treatment [1][2] - The management team of I-Mab will participate in the Jefferies Global Healthcare Conference from June 3-5, 2025, discussing clinical progress on its lead program, givastomig [1][2] - New data on givastomig has been accepted for a Mini Oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain [2] Company Information - I-Mab is headquartered in Rockville, Maryland, and has operations in Short Hills, New Jersey [2] - The company is publicly traded on NASDAQ under the ticker IMAB [1][2] - For more information, I-Mab's website and social media channels are available [2]

Core Insights - Cidara Therapeutics, Inc. is participating in two upcoming investor conferences: RBC Global Healthcare Conference on May 21, 2025, and Jefferies Global Healthcare Conference on June 4, 2025 [1][2] - The company will also engage in one-on-one investor meetings during these events [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, which include targeted small molecules or peptides linked to a human antibody fragment [3] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose, having received Fast Track Designation from the FDA in June 2023 and completing Phase 2b enrollment in December 2024 [3] - Additional DFCs are being developed for oncology, with IND clearance received for CBO421 in July 2024, targeting CD73 in solid tumors [3]